Becton Dickinson and Co (BDX) Shares Sold by Ridgewood Investments LLC

Ridgewood Investments LLC decreased its stake in Becton Dickinson and Co (NYSE:BDX) by 61.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,011 shares of the medical instruments supplier’s stock after selling 4,739 shares during the period. Ridgewood Investments LLC’s holdings in Becton Dickinson and were worth $752,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BDX. Oregon Public Employees Retirement Fund boosted its stake in shares of Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares in the last quarter. Norges Bank purchased a new stake in shares of Becton Dickinson and in the 4th quarter valued at $515,703,000. Morgan Stanley boosted its stake in shares of Becton Dickinson and by 133.0% in the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock valued at $723,303,000 after purchasing an additional 1,581,829 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of Becton Dickinson and by 27.7% in the 4th quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after purchasing an additional 421,825 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Becton Dickinson and by 1.9% in the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after purchasing an additional 355,223 shares in the last quarter. 84.82% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have recently issued reports on BDX. Barclays upped their price objective on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research note on Monday. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Raymond James cut their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research note on Tuesday, March 19th. Finally, TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and an average price target of $256.25.



BDX traded down $0.95 during trading on Monday, hitting $245.76. 40,814 shares of the stock traded hands, compared to its average volume of 1,272,289. The stock has a market capitalization of $66.46 billion, a P/E ratio of 22.30, a PEG ratio of 1.77 and a beta of 1.21. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.48 EPS. Sell-side analysts expect that Becton Dickinson and Co will post 12.08 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.08 annualized dividend and a yield of 1.25%. Becton Dickinson and’s payout ratio is currently 27.97%.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 3,123 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total transaction of $796,458.69. Following the completion of the sale, the chief executive officer now owns 215,372 shares of the company’s stock, valued at approximately $54,926,321.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Ribo Alberto Mas sold 4,808 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total transaction of $1,226,184.24. Following the sale, the executive vice president now directly owns 22,476 shares of the company’s stock, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. Insiders have sold a total of 29,684 shares of company stock valued at $7,518,574 in the last three months. 0.12% of the stock is currently owned by corporate insiders.

WARNING: “Becton Dickinson and Co (BDX) Shares Sold by Ridgewood Investments LLC” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://dakotafinancialnews.com/2019/04/15/becton-dickinson-and-co-bdx-shares-sold-by-ridgewood-investments-llc.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What is the Producer Price Index (PPI)?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.